923 reports of this reaction
3.4% of all BICALUTAMIDE reports
#3 most reported adverse reaction
PROSTATIC SPECIFIC ANTIGEN INCREASED is the #3 most commonly reported adverse reaction for BICALUTAMIDE, manufactured by ANI Pharmaceuticals, Inc.. There are 923 FDA adverse event reports linking BICALUTAMIDE to PROSTATIC SPECIFIC ANTIGEN INCREASED. This represents approximately 3.4% of all 27,404 adverse event reports for this drug.
Patients taking BICALUTAMIDE who experience prostatic specific antigen increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PROSTATIC SPECIFIC ANTIGEN INCREASED is moderately reported among BICALUTAMIDE users, representing a notable but not dominant share of adverse events.
In addition to prostatic specific antigen increased, the following adverse reactions have been reported for BICALUTAMIDE:
The following drugs have also been linked to prostatic specific antigen increased in FDA adverse event reports:
PROSTATIC SPECIFIC ANTIGEN INCREASED has been reported as an adverse event in 923 FDA reports for BICALUTAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PROSTATIC SPECIFIC ANTIGEN INCREASED accounts for approximately 3.4% of all adverse event reports for BICALUTAMIDE, making it one of the most commonly reported side effect.
If you experience prostatic specific antigen increased while taking BICALUTAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.